OverviewChartNewsTraderScreen

Dyadic International/  US26745T1016  /

IEX
2024-04-24  9:59:51 PM Chg. - Volume Bid- Ask- High Low
1.52USD - 1
Turnover: 1.52		 -Bid Size: - -Ask Size: - 1.52 1.52
GlobeNewswire 03-28 Dyadic Reports 2023 Full Year Results and Recent Company Progress
GlobeNewswire 03-28 Dyadic Announces Change in Board and Management Leadership Roles
GlobeNewswire 03-27 Dyadic to Attend Industry Events in April
GlobeNewswire 03-26 Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communica...
GlobeNewswire 03-21 Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
GlobeNewswire 03-14 Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 20...
GlobeNewswire 03-11 CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Acce...
GlobeNewswire 03-11 Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-T...
GlobeNewswire 03-01 Dyadic to Attend Industry Events in March
GlobeNewswire 02-28 Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vacc...
GlobeNewswire 02-21 Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Thr...
GlobeNewswire 02-13 Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality...
GlobeNewswire 02-06 Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Comp...
GlobeNewswire 02-01 Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
Newsfile Corp 01-22 Dyadic International, Inc Invites You to Join Us at The Microcap Conference
GlobeNewswire 01-02 Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
GlobeNewswire 2023-11-30 Dyadic Attends Investor Events in December
GlobeNewswire 2023-11-29 Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Fi...
GlobeNewswire 2023-11-20 Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
GlobeNewswire 2023-11-10 The Benchmark Company Announces Upcoming 12th Annual Discovery One-on-One Investor Conference
GlobeNewswire 2023-11-08 Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
GlobeNewswire 2023-10-30 Dyadic to Present at Industry Events in November
GlobeNewswire 2023-10-25 Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
GlobeNewswire 2023-10-09 Dyadic Appoints Doug Pace to Its Executive Leadership Team
GlobeNewswire 2023-10-05 Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts Gener...